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Abstract 
The glycan supersite centered on N332 in the V3 base of the HIV-1 envelope (Env) is a target for broadly neutralizing 
antibodies (bnAbs) such as PGT121 and PGT128. In this study, we examined the basis of resistance of HIV-1 clade C 
Envs obtained from broadly cross neutralizing (BCN) plasma of an Indian donor with N332 specificity. Pseudotyped 
viruses expressing autologous envs were found to be resistant to autologous BCN plasma as well as to PGT121 and 
PGT128 mAbs despite the majority of Envs containing an intact N332 residue. While resistance of one of the Envs to 
neutralization by autologous plasma antibodies with shorter V1 loop length was found to be correlated with a N332S 
mutation, resistance to neutralization of rest of the Envs was found to be associated with longer V1 loop length and 
acquisition of protective N-glycans. In summary, we show evidence of escape of circulating HIV-1 clade C in an indi-
vidual from autologous BCN antibodies by three distinct mechanisms.
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The HIV-1 envelope (Env) protein that mediates entry of 
viral RNA into the cellular cytoplasm is the target of neu-
tralizing antibodies. During the course of the infection, 
HIV-1 evolves within an individual to escape the humoral 
immune pressure by selection of mutations, alterations of 
the glycosylation pattern and varying loop lengths. Vari-
ation in lengths and glycosylation patterns in the hyper-
variable loops of viral Env, particularly in the V1V2 loop 
has been shown to be associated with alterations in virus 
entry and neutralization [1–14].
Neutralizing antibodies to autologous circulat-
ing HIV-1 develop in most infected individuals within 
6 months [5, 15, 16], however only in some individuals, 
neutralizing antibodies with considerable breadth and 
potency develops over time [17, 18]. Broadly neutralizing 
monoclonal antibodies (bnAbs) isolated from individuals 
infected with HIV-1 have identified major targets in 
the CD4 binding site (CD4bs), the membrane proximal 
external region (MPER), the trimer apex (V1/V2), the 
V3-glycan supersite and the gp120/gp41 interface on the 
HIV-1 Env [19]. Variable loop length (particularly the 
V1V2 loop) and glycosylation signatures within these 
loops have been demonstrated to be selectively associ-
ated with resistance and enhanced sensitivity to some 
bnAbs [6, 7, 9, 10, 20–24].
Glycan supersites in the V3 region of HIV-1 envelope 
form vulnerable targets that are exploited by potent and 
broadly neutralizing monoclonal antibodies (bnAbs) such 
as PGT121 and PGT128 [25]. The glycan N332 residue 
in the V3 base has been demonstrated to represent an 
important supersite of vulnerability for comprehensive 
antibody mediated virus neutralization and is currently 
aiding design and development of an effective vaccine. 
In the case of mAbs PGT121 and PGT128 that target the 
V3-glycan supersite, loss of the glycan at position 332 is 
often associated with resistance [26]. Recently, Goo et al. 
and Sok et al. [26, 27] reported that some viruses despite 
the presence of key N301 and N332 V3 glycans were 
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found to be resistant to the potent and broadly neutral-
izing mAbs, PGT121 and PGT128. They suggested that 
altered conformation of Env due to unknown mecha-
nisms resulted in neutralization resistance of viruses to 
these mAbs. Recently, van den Kerkhof et al. [14] showed 
association of elongated V1 loop length with resist-
ance to patient derived primary Envs to PGT135 mAb. 
In the present study, we examined the basis of resist-
ance of HIV-1 clade C Envs to contemporaneous BCN 
plasma (INDO-SA 2007) obtained from a slow progress-
ing Indian patient whose specificity mapped to the N332 
at the V3 base. By examining HIV-1 Envs obtained from 
BCN plasma of an Indian patient, we found that longer 
V1 loop length hinders the bnAbs such as PGT121 and 
PGT128 to access the N332 glycan epitope. Our obser-
vation provides information that explains the basis of 
resistance of HIV-1 variants that are naturally resistant to 
bnAbs targeting N332 glycan epitope.
We screened 100 HIV-1 positive plasma samples 
obtained from antiretroviral therapy (ART) naïve slow 
progressing Indian donors with a CD4 count >350 mm3 
for the presence of broadly neutralizing antibodies to 
HIV-1 clade C viruses from India (n  =  9) and South 
Africa (n  =  8). Of the 21 plasma samples that were 
found to cross neutralize >50 % of the pseudoviruses at 
1:100 dilution, we identified an Indian donor (INDO-SA 
2007) whose plasma showed the maximum breadth and 
potency with median ID50 of 770 (Fig. 1a). The INDO-
SA 2007 plasma showed geometric mean titer of >749 
when tested against a larger panel of 28 HIV-1 Env pseu-
dotyped viruses primarily comprising Envs of Indian and 
South African clade C origins (Table  1). Interestingly, 
we found that majority of the panel Envs examined con-
tains N332, which is an important target of neutralizing 
antibodies such as PGT128 [11]; however the INDO-SA 
2007 BCN plasma also neutralized Envs that lacks N332 
but contains N334 which has been demonstrated to com-
pensate the function for N332 in a context dependent 
manner [28].
We next examined the specificity of the INDO-SA 2007 
BCN plasma. To test whether the neutralizing antibod-
ies preferably target epitopes on monomeric gp120 or 
trimeric gp140, plasma was depleted with monomeric 
gp120 (from strain 4-2.J41 containing N334) [29] and 
trimeric gp140 (made using BG505-SOSIP.664 con-
taining N332) proteins [30]. As shown in Table  2A, we 
found a significant reduction in neutralization sensitiv-
ity of selected heterologous Env-pseudotyped viruses to 
INDO-SA 2007 BCN plasma depleted with both mono-
meric gp120 and trimeric gp140. We next tested if the 
INDO-SA 2007 bnAb possess specificity to known bnAb 
targets such as (1) CD4bs by examining neutralization of 
Env-pseudotyped viruses (25711-2.4) in the presence of 
the CD4bs competitors, RSC3 and TripleMut proteins 
[31, 32], (2) V2/V3 epitopes by examining ability of the 
BCN plasma antibodies to neutralize a battery of Env 
mutants that removes the key epitopes targeted by bnAbs 
and (3) MPER by examining neutralization of HIV-2/
HIV-1 MPER chimeric viruses to the BCN plasma anti-
bodies [33, 34]. The INDO-SA 2007 BCN plasma pre-
treated with RSC3 and TripleMut core protein was found 
to show comparable neutralization of Env-pseudotyped 
virus (25711-2.4) to that of the plasma not treated with 
RSC3 core protein (Fig. 1b). Our data indicated that the 
INDO-SA 2007 BCN plasma did not possess CD4bs 
directed antibodies associated with virus neutralization. 
When examined for the presence of antibodies that are 
dependent on known epitopes in gp120 variable regions, 
Fig. 1 a Neutralization potency of BCN plasma samples against pseudoviruses expressing HIV-1 clade C Indian and South African Envs. b Dose–
response curves showing the degree of neutralization of Env-pseudotyped virus (25711-2.4) mediated by INDO-SA 2007 plasma pre-treated with 
RSC3 core protein
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neutralization by INDO-SA 2007 plasma was not found 
to depend on epitopes such as, N160, R166, and K169 in 
the V2 (Table 2B). However, a 2.42 and >5-fold reduction 
in neutralization of the two Env-pseudotyped viruses 
(25711-2.4 and CAP239.G3) with N301A and N332A 
substitutions in V3 respectively compared to their wild 
types were observed (Table  2B). Finally, presence of 
MPER directed neutralizing antibodies was examined 
by investigating the degree of neutralization of HIV-2/
HIV-1 chimeric viruses expressing HIV-1 clade C com-
plete MPER region (C1C), 4E10, Z13e, 10E8 overlapping 
epitopes (C4) and 4E10 minimal epitope (C6). As shown 
in Table 2C, while antibody titer against C1C was found 
to be very low and insignificant (ID50 of 63.77), no neu-
tralization of HIV-2/HIV-1 chimera expressing C4 and 
C6 constructs were observed by the INDO-SA 2007 
plasma antibodies. Our data indicate that the neutraliza-
tion breadth mediated by the INDO-SA 2007 plasma was 
not due to presence of antibodies targeting MPER. Taken 
together, our data indicate that the neutralizing antibod-
ies present in the INDO-SA 2007 plasma targets both lin-
ear and conformational epitopes in gp120 and which are 
dependent on N332 glycan in the V3 region. Nonethe-
less, as shown in Table 1, since the INSO-SA 2007 plasma 
was found to also neutralize pseudoviruses expressing 
Envs lacking N332 (such as 00836-2.5 and 16055-2.3), it 
likely has other specificities besides N301 and N332.
We next examined the pseudotyped viruses express-
ing contemporaneous autologous env genes ampli-
fied from the INDO-SA 2007 plasma for their degree of 
Table 1 Neutralization breadth of the INDO-SA 2007 BCN plasma antibodies
a The V1 loop sequence of 92BR020 and 94UG103are unavailable in the NCBI GenBank database. ID50 values refer to the reciprocal dilution that conferred 50 % 
neutralization of viruses in a TZM-bl assay. Assays were done in duplicates and were repeated more than three times
Origin Envs (n = 28) Tier GenBank Tier Accession No ID50 values V1 loop length N332/N334
Negative virus controls MuLV DQ359272.1 <20 N/A
HIV-2 (7312A) L36874 <20 N/A
India C (n = 9) 00836-2.5 2 EF117265 450 21 Absent
25711-2.4 1B EF117272 2789 25 N332
26191-2.48 2 EF117274 500 16 N332
16055-2.3 2 EF117268 382 23 Absent
16936-2.21 2 EF117270 694 20 N332
4-2.J41 – GU945316.2 705 19 N334
5-4.J16 – GU945326.1 1233 21 N332
7-J.20 – EU908223.1 1384 23 N332
11-5.J12 – GU945332.1 2715 18 N334
South Africa C (n = 8) Du151.2 2 DQ411851.1 249 17 N332
Du156.12 2 DQ411852.1 770 24 N332
Du172.17 2 DQ411853.1 1019 29 N332
Du422.1 2 DQ411854.1 246 26 N332
CAP45.G3 2 DQ435682.1 710 16 N334
CAP84.32 2 EF203963.1 1017 15 N332
CAP88.B5 2 EF203972.1 793 28 N332
CAP239.G3 2 EF203983.1 1090 17 N332
Others (n = 11) JRFL 2 U63632.1 97 24 N332
JRCSF 2 M38429.1 1527 24 N332
PVO.4 3 AY835444.1 553 29 N332
SC422661.8 2 AY835441.1 744 23 N332
RHPA4259.7 2 AY835447.1 871 22 N332
92BR020 1 AY669718.1 1015 a N332
92TH021 2 AY669775.1 322 28 N334
93IN905 2 AY669742.1 6896 15 N332
94UG103 2 AY669705.1 108 a N332
191727_D1.12 – HM215267.1 <50 30 –
IAVI C22 – – 1940 – –
Geometric Mean Titer 749
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sensitivity to the contemporaneous autologous plasma 
antibodies. The autologous envs were found to belong 
to HIV-1 clade C as determined by REGA HIV subtyp-
ing tool version 2 (http://www.bioafrica.net/rega-gen-
otype/html/). The genetic properties of the autologous 
env clones are shown in Table 3 and Fig. 2a. Analysis of 
the complete amino acid (gp160) sequences of all the 
Envs (HIV-1 NLR-2007.J10, HIV-1 NLR-2007.J12, HIV-1 
NLR-2007.J24, HIV-1 NLR-2007.J32 and HIV-1 NLR-
2007.J48) revealed that they form a monophyletic cluster 
lineage with those of other Indian clade C Envs used in 
this study (Fig.  2a). Interestingly, four of the autologous 
Envs (HIV-1 NLR-2007.J10, HIV-1 NLR-2007.J12, HIV-1 
NLR-2007.J24, HIV-1 NLR-2007.J32) obtained from this 
donor were found to possess longer V1 loop length with 
identical amino acid sequence (Fig.  2b) consisting of 41 
amino acids compared to HIV-1 NLR-2007.J48 that was 
found to contain 27 amino acids in the V1 region. Envs 
with longer V1 loop were also found to possess more 
glycan residues (5N-linked glycan residues) than that of 
HIV-1 NLR-2007.J48 possessing shorter V1 loop length 
(2N-linked glycan residues) (Table  3). Nonetheless, 
all the Envs (irrespective of shorter or longer V1 loop 
lengths as well as variable glycan content) obtained from 
this donor were found to be resistant to the contempo-
raneous autologous INDO-SA 2007 plasma (Table  3). 
Since the INDO-SA 2007 plasma was found to possess 
N332-specific antibodies (Table  2B), we next examined 
Table 2 A. Fold changes in neutralization sensitivity of the Env-pseudotyped viruses to INDO-SA 2007 plasma depleted 
with the monomeric (4-2.J41) gp120 and trimeric (BG505-SOSIP.664) gp140 proteins. B. Specificity of INDO-SA 2007 BCN 
plasma antibodies to known epitopes in variable loops. C. Presence of MPER directed neutralizing antibodies in INDO-SA 
2007 plasma
a Fold reduction in neutralization of Env-pseudotyped viruses was obtained by comparing the neutralization titer (ID50 values) of panel viruses against undepleted 
and depleted INDO-SA 2007 plasma. ID50 values are reciprocal dilutions at which the undepleted and depleted plasma conferred 50 % neutralization of the Env-
pseudotyped viruses in TZM-bl cells
b ID50 values refer to the reciprocal dilution that conferred 50 % neutralization of viruses in a TZM-bl assay. Assays were done in duplicates and were repeated more 
than three times. WT refers to wild type; MPER refers to membrane proximal external region in gp41
c HIV-1 MPER residues that are grafted in the HIV-2 are given in the parenthesis
A Fold decrease in ID50 
a








HIV-1 Env mutants Region Neutralization titer (ID50) Fold decrease in ID50 
b
HIV-1 25711-2.4 Wild type 1822.04 –
HIV-1 CAP239.G3 Wild type 1096.00 –
HIV-1 25711-2.4 N160A V2 1484.35 1.22
HIV-1 CAP239.G3 N160A V2 4184.00 0.26
HIV-1 25711-2.4 R166A V2 1833.00 0.99
HIV-1 25711-2.4 K169E V2 2587.29 0.70
HIV-1 25711-2.4 N301A V3 stem 749.81 2.42
HIV-1 25711-2.4 N332A V3 stem 357.36 5.09
HIV-1 CAP239.G3 N332A V3 stem 204.60 5.35
C
HIV-2/HIV-1 chimera Region of HIV-1c ID50
HIV-2 7312A HIV-2 wild type <20
HIV-2 7312A-C1C Clade C MPER (ELLALDKWASLWNWFDITKWLWYIK) 63.77
HIV-2 7312A-C4 4E10 epitope (NWFDITKWLWYIK) <20
HIV-2 7312A-C6 4E10 minimal (NWFDIT) <20
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the neutralization sensitivity of the autologous Envs 
to PGT121 and PGT128, which are potent mAbs that 
specifically targets these glycan epitopes. As shown in 
Table 3, all the autologous Envs were found to be resist-
ant to both the mAbs (up to 10  µg/ml) thus showing a 
clear association between neutralization resistance of 
autologous Envs to INDO-SA 2007 plasma and both 
PGT121 and PGT128 mAbs. Sequence data revealed 
that except one (HIV-1 NLR-2007.J48 with shorter V1 
loop length and containing a serine at the 332 position 
in V3 base), all the other autologous Envs contains an 
N332-glycan (Fig.  2c), suggesting that these later Envs 
were evolved with other features that prevented the 
N332glycan-specific neutralizing antibodies to access 
this epitope, possibly by concealing its optimal exposure 
due to a conformational change. Upon substituting the 
naturally occurring serine residue with a glycan at the 
332 position (S332N), the sensitivity of the HIV-1 NLR-
2007.J48 Env to autologous plasma, PGT121 and PGT128 
mAbs was found to increase by 10, >80 and >100 folds 
respectively (Table  4). Thus, while the N332S mutation 
mediated neutralization resistance of HIV-1 NLR-2007.
J48 Env, the other contemporaneous Envs despite natu-
rally expressing N332 were found not to be susceptible to 
N332-specific neutralizing antibodies including PGT121 
and PGT128, possibly due to attaining a distinct confor-
mation that prevented accessing the N332 glycan epitope 
by these potent neutralizing antibodies.  
To further elucidate the cause of resistance of N332-gly-
can containing autologous Envs to N332-glycan spe-
cific INDO-SA 2007 bnAb plasma activity, PGT121 
and PGT128 mAbs, we first compared the amino acid 
sequences of the HIV-1 NLR-2007.J48 with that of other 
four contemporaneous Envs (HIV-1 NLR-2007.J10, HIV-1 
NLR-2007.J12, HIV-1 NLR-2007.J24 and HIV-1 NLR-
2007.J32) that naturally contain the N332 glycan resi-
due. All these Envs were found to have identical V3 loop 
sequence (except for HIV-1 NLR-2007.J48 having two 
amino acid differences) and contained the IGDIR motif 
including the glycans in the V3 loop shown to be impor-
tant for PGT128 sensitivity [28]. Interestingly, we found a 
positive association between shorter V1 loops and suscep-
tibility of the heterologous Envs tested against the INSO-
SA 2007 bnAb plasma activity (Table 1) too. In order to 
Fig. 2 a Inter and intra-clade genetic relatedness of INSO-SA 2007 autologous HIV-1 clade C env (gp160) amino acids. Maximum likelihood phyloge-
netic tree was constructed with 50 bootstrapped replicates and inferred by using Jones–Taylor–Thornton (JTT) model [35]. Values next to the nodes 
of each branch indicate percentage of trees in which the associated taxa are clustered together. Branch length represents residues substitution per 
site. The scale shown at the bottom of the tree indicates 0.02 substitutions per amino acid residue. b Alignment of amino acid sequences of V1 loop 
of autologous envs. N-linked glycans are highlighted in red and their positions are highlighted. c Comparison of amino acid sequences between 
the V3 region of the autologous HIV-1 env clones. Amino acid sequences were aligned using ClustalW algorithm using Mega 5.2 program and the 
alignment file was further processed in Seqpublish tool which is available in www.hiv.lanl.gov. The N301 and N332 glycan residues including the 
core amino acid motif IGDIR important for PGT128 sensitivity are highlighted. Amino acid numbering was done relative to HXBc2 (http://www.hiv.
lanl.gov/content/sequence/HIV/REVIEWS/HXB2.html)
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determine whether longer V1 loop length was associ-
ated with neutralization resistance of autologous Envs to 
N332 directed neutralizing antibodies, we next exchanged 
the V1 domain between HIV-1 NLR-2007.J48 (S332N) 
and HIV-1 NLR-2007.J12 and examined susceptibil-
ity to the INDO-SA 2007 plasma, PGT121 and PGT128 
mAbs. As shown in Table  4, while HIV-1 NLR-2007.J12 
expressing V1 region of HIV-1 NLR-2007.J48 (S332N) 
(shorter V1 loop) became sensitive to both PGT121 and 
PGT128 mAbs; HIV-1 NLR-2007.J48 (S332N) containing 
V1 loop of the HIV-1 NLR-2007.J12 Env became resist-
ant to the PGT121 and PGT128 mAbs by >17 and >100-
fold respectively. As shown in Table  3 and Fig.  2b, we 
also found that while HIV-1 NLR-2007.J48 contains two 
glycan residues (N136, N144), the other four contempo-
raneous Envs contain five glycan residues (N139, N142, 
N145g, N145l, N147) within the V1 loop. Interestingly, 
as shown in Table 4, presence of N136, N144 residues in 
the HIV-1 NLR-2007.J48 did not modulate its sensitiv-
ity to the neutralization by both autologous BCN plasma 
and the PGT121 as well as PGT128 mAbs, suggesting 
that these two glycans did not play any protective role. 
So, to further examine whether glycan residues present 
in the other Envs with longer V1 loop length as shown 
in Table 3 played any role in neutralization resistance to 
the antibodies tested in our study, we carried out site-
directed mutagenesis to substitute N-glycans with alanine 
residues. As shown in Table 4, knocking out of these gly-
can residues was found to be correlated significantly with 
increased susceptibility of the NLR-2007.J12 Env (N139A/
N142A/N145gA, N145lA/N147A) with longer V1 loop to 
PGT121 and PGT128 mAbs by >20 and >35 folds respec-
tively. However, only 1.9-fold increase in neutralization of 
NLR-2007.J12 (N139A/N142A/N145gA, N145lA/N147A) 
to autologous plasma antibodies was observed. Our data 
indicated that while incorporation of protective glycan 
residues conferred significant resistant of Envs to PGT121 
and PGT128 mAbs, it moderately mediated resistance of 
Envs to contemporaneous INDO-SA 2007 plasma anti-
bodies, indicating that longer V1 loop length had more 
influence on neutralization resistance over the protective 
glycan residues. Interestingly, as per the HIV Los Alamos 
CATNAP database (http://www.hiv.lanl.gov/content/
immunology/neutralizing_ab_resources.html), viruses 
containing N332 glycan residue and with unusually longer 
V1 loop length (37–47 amino acids) were found to be 
resistant to PGT121 (67  %) and PGT128 (59  %) mAbs, 
indicating a modest association between V1 loop length 
and virus resistance to PGT121/128 mAbs. Our study also 
demonstrated that neither longer V1 loop length nor its 
glycosylation pattern was found to influence the suscep-
tibility of Env to b12, VRC01 mAbs, which is in contrast 
to the recent finding by van den Kerkhof et al. [14] where 
longer V1 loop length associated with resistance to b12 
mAb was reported.
In summary, our data provide evidence that the circu-
lating HIV-1 clade C in this elite neutralizer escaped the 
neutralization by the autologous plasma in this patient via 
three distinct mechanisms: (1) due to a N332S mutation 
(2) by increasing V1 loop length and (3) incorporation of 
protective N-glycan residues in V1 loop. These features 
hindered the neutralizing antibodies, developed in this 
donor, to optimally access the N332 epitope. Addition-
ally, we show that these features also conferred resistance 
to PGT121 and PGT128 mAbs that also targets N332 
epitope in the V3 base. Although an association between 
expanded V1 loop length and sensitivity of HIV-1 Env to 
PGT135 mAb but not to the PGT121 and PGT128 mAbs 
have very recently been demonstrated [14], our observa-
tion on the association between expanded V1 loop with 
resistance to PGT121 and PGT128 was possibly due to 
differences in the angle of approach of these mAbs to 
N332 glycan residue compared to that of PGT135 as 
demonstrated by van den Kerkhof et  al. [14] and Kong 
et al. [25].
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